Governance
Editorial Standards
Accuracy; fairness; neutral language; source standards; pharmacy profiles; adverse findings; updates; corrections.
This page covers compounding editorial standards. It documents how this platform verifies, labels, and publishes regulatory records, and the limits it places on itself. Every entity-specific field that has not been verified against a primary source renders as Verification Pending rather than being inferred.
Key findings
- Primary focus: Accuracy.
- Registration with FDA is not FDA approval, and a state licence is not a quality assessment.
- Unverified fields render fail-closed; no badge, score, or ranking is generated from missing data.
- Current and historical records are separated and labelled distinctly.
- Named entities may respond to any record through the right-to-respond process.
| Accuracy | Verification Pending |
|---|---|
| Fairness | Verification Pending |
| Neutral language | Verification Pending |
| Source standards | Verification Pending |
| Pharmacy profiles | Verification Pending |
| Adverse findings | Verification Pending |
| Federal framework | License Verified FDA sources verified 2026-07-23 |
| Entity-specific data | Verification Pending |
What is established about accuracy?
For compounding editorial standards, accuracy is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where accuracy has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about fairness?
For compounding editorial standards, fairness is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where fairness has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about neutral language?
For compounding editorial standards, neutral language is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where neutral language has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about source standards?
For compounding editorial standards, source standards is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where source standards has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about pharmacy profiles?
For compounding editorial standards, pharmacy profiles is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where pharmacy profiles has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What does this page establish?
It establishes the framework and the source map for compounding editorial standards, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.
What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.
The federal framework, as stated by FDA
| Point | What FDA states | Source |
|---|---|---|
| Dqsa | The Drug Quality and Security Act was signed into law on 27 November 2013 and added section 503B to the Federal Food, Drug, and Cosmetic Act, creating outsourcing facilities. | FDA |
| 503B Def | An outsourcing facility is defined as a facility at one geographic location engaged in compounding sterile drugs, that has elected to register as an outsourcing facility, and complies with a | FDA |
| 503B Cgmp | Drugs compounded by an outsourcing facility can qualify for exemptions from FDA approval requirements and from the requirement to label products with adequate directions for use, but not fro | FDA |
| Reg Not Approval | Registration means only that FDA has received the information required to register the facility. It does not mean the facility is making FDA-approved drugs, and it does not mean it complies | FDA |
| Not Approved | Drugs made by compounders, including those made at outsourcing facilities, are not FDA-approved. They have not undergone the same premarket review as approved drugs and lack FDA review of sa | FDA |
| Risk Based | Outsourcing facilities are inspected by FDA according to a risk-based schedule. Inspection frequency depends on prior findings, compliance history, recall history, and the inherent risk of t | FDA |
| 503A Def | Section 503A describes conditions under which drug products compounded by a licensed pharmacist in a state-licensed pharmacy, or by a licensed physician, are exempt from FDA approval, CGMP, | FDA |
What this means
- The framework governing compounding editorial standards is cited to FDA primary sources.
- The record holding each element of accuracy is named.
- Verification dates are published on every field so staleness is visible.
What this does not mean
- That any entity connected with compounding editorial standards is compliant or non-compliant.
- That the absence of a record indicates the absence of an issue.
- That this platform certifies or endorses any facility or preparation.
Status terms on this page follow the platform's published status vocabulary.
- No entity-specific record relating to compounding editorial standards has been verified at this snapshot.
- Accuracy may change without notice to this platform.
- Regulatory positions change through rulemaking, guidance, and enforcement action.
- Records held by different agencies may disagree; conflicts are published as conflicts.
Sources verified for this page — 10 sources
- FDA — Information for Outsourcing Facilitieschecked 2026-07-23
- FDA — Q&A: Outsourcing Facility Registrationchecked 2026-07-23
- FDA — Registered Outsourcing Facilitieschecked 2026-07-23
- FDA — Aligning Federal and State Regulation of Compounderschecked 2026-07-23
- FDA — Outsourcing Facility Feeschecked 2026-07-23
- FDA — Compounded Drug Products That Are Essentially Copieschecked 2026-07-23
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)checked 2026-07-23
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)checked 2026-07-23
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)checked 2026-07-23
- FDA — Outsourcing Facility Fees guidancechecked 2026-07-23
Why compounding editorial standards is hard to verify
Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.
First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.
That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.
| Structural feature | Consequence for verification | How this platform handles it |
|---|---|---|
| Split federal and state authority | No single register is complete for any entity | Both systems are named per field, and neither is presented as sufficient |
| Registration precedes inspection | A registration is not evidence of oversight | Registration and inspection are reported as separate facts |
| Records go stale silently | A citation without a date implies currency it may not have | Every field carries its own verification date |
| Observations are not findings | A Form 483 is frequently reported as a violation | Observations and final actions are stored and displayed separately |
| Resolved actions persist online | Closed matters get reported as current | Current and historical status are distinct states, never merged |
What does this policy actually constrain?
A governance page is only worth reading if it changes what the site may publish. This one constrains compounding editorial standards: it fixes what evidence is required before a statement about a named entity can appear, and what must render instead when that evidence is absent.
The constraint is enforced in the build rather than by editorial habit. Fields without a verified source render as an explicit status; a status outside the published vocabulary raises an error and stops the build; and pages whose only official datum is shared verbatim with other pages are withheld from search entirely.
| Rule | What it prevents | Where it is enforced |
|---|---|---|
| An entity claim needs a named source and a date | Inference presented as fact | Build-time field validation |
| Status terms come from a fixed vocabulary | Adjective drift into judgement | Status function rejects unknown codes |
| Observations are separated from final findings | A Form 483 read as a violation | Separate fields and display states |
| Current and historical are distinct states | Resolved matters shown as current | Separate status codes |
| Absence is never a finding | Missing record read as clean or as concerning | Explicit 'No Public Evidence Found' status |
| No badge, score or ranking of entities | Composite judgement without evidence | No scoring function exists in the codebase |
What this policy costs
Every constraint above has a price, and it is worth naming rather than presenting the policy as free. Fail-closed fields make pages visibly incomplete. Refusing composite scores means this platform cannot answer 'which pharmacy is best', which is the question most readers arrive with. Withholding pages without unique official data means large parts of the architecture stay unindexed.
Those are deliberate trades. A platform that names real businesses and publishes regulatory records about them has a duty of accuracy higher than ordinary editorial content, and the cost of being wrong falls on the entity rather than on the publisher.
Related records in this section
Section hub: Governance · Methodology · Status definitions · Right to respond
Frequently asked questions
What does this page cover on compounding editorial standards?
Accuracy; fairness; neutral language; source standards; pharmacy profiles; adverse findings; updates; corrections.
What is established about accuracy?
Accuracy is tracked as part of compounding editorial standards. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about fairness?
fairness is tracked as part of compounding editorial standards. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about neutral language?
neutral language is tracked as part of compounding editorial standards. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
How does this governance rule apply to compounding editorial standards?
It constrains what may be published: an entity-specific claim must resolve to a named official source with a verification date, or it renders as an explicit status instead.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
- FDA — Aligning Federal and State Regulation of Compounders
- FDA — Outsourcing Facility Fees
- FDA — Compounded Drug Products That Are Essentially Copies
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
- FDA — Outsourcing Facility Fees guidance
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.